| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1107686364 |
| P356 | DOI | 10.1186/S12974-018-1330-2 |
| P932 | PMC publication ID | 6192101 |
| P698 | PubMed publication ID | 30333036 |
| P50 | author | Yiwei Chu | Q88638221 |
| P2093 | author name string | Bo Wang | |
| Chen Wang | |||
| Ronghua Liu | |||
| Chujun Zhao | |||
| Jiao Yang | |||
| Feifei Luo | |||
| Jiawen Qian | |||
| Yuedi Wang | |||
| Junying Xu | |||
| P2860 | cites work | Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer’s Disease. | Q55405257 |
| PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis | Q57083098 | ||
| Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. | Q64955888 | ||
| Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18 | Q74108232 | ||
| Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis | Q79209903 | ||
| TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia | Q91068371 | ||
| GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals | Q24310380 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| CTLA-4 ligation blocks CD28-dependent T cell activation | Q24678229 | ||
| SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition | Q27676669 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Q29620812 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. | Q34076317 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. | Q35677893 | ||
| Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity | Q35822851 | ||
| PD-L1 expression and prognostic impact in glioblastoma | Q36493843 | ||
| B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients | Q36963632 | ||
| Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma | Q37477267 | ||
| Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? | Q37492248 | ||
| Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy | Q37741143 | ||
| Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model | Q37814208 | ||
| Immune microenvironment of gliomas | Q38712457 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. | Q39003387 | ||
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
| PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction | Q39206599 | ||
| Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. | Q39930421 | ||
| PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells | Q40163138 | ||
| CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells | Q40619963 | ||
| T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas | Q41024072 | ||
| PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Q41526004 | ||
| GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. | Q41870476 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. | Q46108181 | ||
| Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice | Q46463474 | ||
| DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. | Q47113174 | ||
| PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients | Q47679044 | ||
| First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. | Q47717093 | ||
| Role of immune microenvironment in gastrointestinal stromal tumours. | Q47856440 | ||
| The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site | Q47936664 | ||
| Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. | Q48091555 | ||
| Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells | Q50107002 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunology | Q101929 |
| P304 | page(s) | 290 | |
| P577 | publication date | 2018-10-17 | |
| P1433 | published in | Journal of Neuroinflammation | Q15716679 |
| P1476 | title | The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy | |
| P478 | volume | 15 |
| Q96128311 | ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma |
| Q64102974 | Distinct interferon signatures stratify inflammatory and dysimmune myopathies |
| Q64083844 | Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma |
| Q89907531 | IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma |
| Q91711786 | NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes |
| Q90069145 | Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling |
| Q97525213 | PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis |
| Q64290717 | RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
Search more.